Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the ...

Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Week-48 suppression was 91.8% with DOR/ISL vs 90.6% with BIC/FTC/TAF, with few discontinuations for inefficacy and similar overall tolerability. EMBRACE reported 12-month suppression rates of 94% (IV ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a ...

Benitec Biopharma Inc., a biotechnology company based in Hayward, California, has announced the acceptance of a late-breaking oral abstract for its ongoing BB-301 Phase 1b/2a Clinical Treatment Study ...